Orexo: Zubsolv Rx Data week 49

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.97% (6.03%), 4-week rolling average. The total number of Zubsolv tablets sold week 49 (48) reaching 337,072 (347,959). Zubsolv prescriptions (TRx) recorded a market share of 5.98% (6.07%), 4-week rolling average. Total number of prescriptions reaching 11,865 (12,413) during the week.

The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 7.6% (7.3%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 6.6% (6.3%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-01-17 Update
2017-01-16 Update
2017-01-16 Update
2017-01-13 Update
2017-01-10 Update
2017-01-10 Update
2017-01-09 Update
2017-01-09 Analys
2016-12-29 Update
2016-12-28 Update
2016-12-27 Update
2016-12-27 Update
2016-12-23 Update
2016-12-22 Update
2016-12-22 Update
2016-12-22 Update
2016-12-21 Update
2016-12-20 Update
2016-12-16 Update
2016-12-14 Update
2016-12-14 Update
2016-12-14 Update
2016-12-14 Analys
2016-12-12 Update
2016-12-12 Update